摘要
目的探讨奥氮平和利培酮治疗慢性精神分裂症的临床疗效和不良反应。方法纳入79例慢性精神分裂症患者按照不同的治疗方案分为利培酮口服液组和奥氮平组进行治疗观察,利培酮口服液组(n=40)患者给予利培酮治疗,奥氮平组(n=39)患者给予奥氮平治疗,疗程2个月,采用阳性和阴性症状量表(PANSS)和不良反应量表(TESS)评定疗效和不良反应。结果利培酮口服液组痊愈1例,显效5例,好转16例,无效18例,有效率为55%,奥氮平组无痊愈患者,显效2例,好转20,无效17例,有效率为56.4%。利培酮口服液组与奥氮平主要不良反应发生率比较,差异无显著性意义(P>0.05)。结论利培酮口服液与奥氮平对慢性精神分裂症的疗效相当,均安全有效,长期疗效如何还需进一步观察。
Objective To compare the clinical effect and security of risperidone oral liquid and olanzapine in the treatment of chronic schizophrenia. Methods To divided 79 cases of chronic schizophre into the risperidone group（n=40） and olanzapine group（n=39）. Patients inthe two groups were given risperidone or olanzapine. Evaluate the clinical effect and security after 2 months reatment. Results Oral risperidone group recovered one case, 5 cases markedly improved in 16 cases, 18 cases, the effective rate was 55%, olanzapine was no cure patients, 2 cases markedly improved in 20, ineffective in 17 cases, the effective rate was 56.4%. There was no obvious difference between the total effective rate oral risperidone group and olanzapine group（P〈0.05）. Conclusion There is little difference of clinical effect between the two drugs when their types of adverse reaction are different. It should be choose the right drug according to the condition of the patients.
出处
《中国医药指南》
2013年第32期421-422,共2页
Guide of China Medicine
关键词
精神分裂症
奥氮平
利培酮
对照研究
Risperidone
Olanzapine
Chronic schizophrenia
Clinical effect
